XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Reporting (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30, |  |
| 2025 |  | 2024 |  | 2025 |  | 2024 |  |
Total revenue (a) | $ | 22,241 |  |  | $ | 10,797 |  |  | $ | 35,434 |  |  | $ | 19,901 |  |  |
Cost of product sales | — |  |  | 176 |  |  | — |  |  | 446 |  |  |
Cost of manufacturing services | 8,906 |  |  | 2,647 |  |  | 14,306 |  |  | 4,493 |  |  |
Research and development expenses: |  |  |  |  |  |  |  |  |
Lorigerlimab | 10,547 |  |  | 11,009 |  |  | 19,425 |  |  | 20,625 |  |  |
MGC030 | 5,666 |  |  | 1,636 |  |  | 8,172 |  |  | 4,911 |  |  |
MGC028 | 4,742 |  |  | 9,678 |  |  | 8,676 |  |  | 15,882 |  |  |
Vobramitamab duocarmazine | 4,386 |  |  | 12,038 |  |  | 12,653 |  |  | 21,706 |  |  |
Next-generation T-cell engagers | 3,516 |  |  | 2,091 |  |  | 5,789 |  |  | 4,580 |  |  |
MGC026 | 2,961 |  |  | 3,895 |  |  | 8,914 |  |  | 7,852 |  |  |
MGD024 | 2,715 |  |  | 2,154 |  |  | 4,907 |  |  | 4,939 |  |  |
Preclinical antibody-drug conjugates (ADCs) | 2,058 |  |  | 3,041 |  |  | 3,857 |  |  | 4,364 |  |  |
Margetuximab | 437 |  |  | 2,868 |  |  | 756 |  |  | 5,982 |  |  |
Other programs | 3,763 |  |  | 3,322 |  |  | 7,340 |  |  | 6,919 |  |  |
Total research and development expenses | 40,791 |  |  | 51,732 |  |  | 80,489 |  |  | 97,760 |  |  |
Selling, general and administrative expenses | 9,302 |  |  | 14,423 |  |  | 20,020 |  |  | 29,133 |  |  |
Other segment income, net (b) | 507 |  |  | 2,517 |  |  | 2,094 |  |  | 4,077 |  |  |
Net loss | $ | (36,251) |  |  | $ | (55,664) |  |  | $ | (77,287) |  |  | $ | (107,854) |  |  |
(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements. (b) Other segment income, net includes interest and other income and interest and other expense.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration